CYP3A4 mutation causes vitamin D–dependent rickets type 3
暂无分享,去创建一个
H. Hakonarson | P. Ebeling | M. Javaid | M. Levine | K. Thummel | N. Shaw | Dong Li | C. Rodda | T. Thacher | Hanh H. Nguyen | J. Roizen | L. O’Lear | Jeffrey D. Roizen
[1] H. Hakonarson,et al. CYP3A4 Induction by Rifampin: An Alternative Pathway for Vitamin D Inactivation in Patients With CYP24A1 Mutations , 2017, The Journal of clinical endocrinology and metabolism.
[2] M. Levine,et al. CYP2R1 Mutations Impair Generation of 25-hydroxyvitamin D and Cause an Atypical Form of Vitamin D Deficiency. , 2015, The Journal of clinical endocrinology and metabolism.
[3] Yanfeng Wang,et al. Comparison of two endogenous biomarkers of CYP3A4 activity in a drug–drug interaction study between midostaurin and rifampicin , 2014, European Journal of Clinical Pharmacology.
[4] Dong Li,et al. Autosomal dominant hypoparathyroidism caused by germline mutation in GNA11: phenotypic and molecular characterization. , 2014, The Journal of clinical endocrinology and metabolism.
[5] C. Peterson,et al. Comparative analysis of human CYP3A4 and rat CYP3A1 induction and relevant gene expression by bisphenol A and diethylstilbestrol: implications for toxicity testing paradigms. , 2013, Reproductive toxicology.
[6] D. Eaton,et al. Enhancement of hepatic 4‐hydroxylation of 25‐hydroxyvitamin D3 through CYP3A4 induction in vitro and in vivo: Implications for drug‐induced osteomalacia , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[7] E. Schuetz,et al. Human PXR-mediated induction of intestinal CYP3A4 attenuates 1α,25-dihydroxyvitamin D₃ function in human colon adenocarcinoma LS180 cells. , 2012, Biochemical pharmacology.
[8] T. Baillie,et al. An Inducible Cytochrome P450 3A4-Dependent Vitamin D Catabolic Pathway , 2012, Molecular Pharmacology.
[9] Kenneth E Thummel,et al. Simultaneous measurement of plasma vitamin D(3) metabolites, including 4β,25-dihydroxyvitamin D(3), using liquid chromatography-tandem mass spectrometry. , 2011, Analytical biochemistry.
[10] Natasha T. Snider,et al. Effects of a Commonly Occurring Genetic Polymorphism of Human CYP3A4 (I118V) on the Metabolism of Anandamide , 2010, Drug Metabolism and Disposition.
[11] A. Halpern,et al. Estimated equivalency of vitamin D production from natural sun exposure versus oral vitamin D supplementation across seasons at two US latitudes. , 2010, Journal of the American Academy of Dermatology.
[12] Ravinder J. Singh,et al. Comparison of Metabolism of Vitamins D2 and D3 in Children With Nutritional Rickets , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[13] K. Han,et al. The CYP3A4*18 Genotype in the Cytochrome P450 3A4 Gene, a Rapid Metabolizer of Sex Steroids, Is Associated With Low Bone Mineral Density , 2009, Clinical pharmacology and therapeutics.
[14] L. Bertilsson,et al. 4&bgr;-Hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians , 2008, Pharmacogenetics and genomics.
[15] J. Halpert,et al. CYP3A4 is a vitamin D-24- and 25-hydroxylase: analysis of structure function by site-directed mutagenesis. , 2005, The Journal of clinical endocrinology and metabolism.
[16] Jeffrey B. Cheng,et al. Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[17] J. Adams,et al. Heterogeneous nuclear ribonucleoprotein (hnRNP) binding to hormone response elements: A cause of vitamin D resistance , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[18] K. Inouye,et al. Dual metabolic pathway of 25-hydroxyvitamin D3 catalyzed by human CYP24. , 2000, European journal of biochemistry.
[19] J. Halpert,et al. Structure-function analysis of human cytochrome P450 3A4 using 7-alkoxycoumarins as active-site probes. , 2000, Archives of biochemistry and biophysics.
[20] S. Kato,et al. Inactivating mutations in the 25-hydroxyvitamin D3 1alpha-hydroxylase gene in patients with pseudovitamin D-deficiency rickets. , 1998, The New England journal of medicine.
[21] Grazyna D. Szklarz,et al. Molecular modeling of cytochrome P450 3A4 , 1997, J. Comput. Aided Mol. Des..
[22] R. Ray,et al. Target cell metabolism of 1,25-dihydroxyvitamin D3 to calcitroic acid. Evidence for a pathway in kidney and bone involving 24-oxidation. , 1989, The Biochemical journal.
[23] M. Haussler,et al. Vitamin D3--resistant fibroblasts have immunoassayable 1,25-dihydroxyvitamin D3 receptors. , 1984, Science.